

ASX Release

SUDA LTD COMMENCES OUTREACH IN THE USA

- Commencing second phase of business development outreach
- Exhibiting on the Australian pavilion at the approx. 20,000-attendee BIO International Convention - 23-26 June 2014 in San Diego, CA
- Meeting with 38 international pharmaceutical companies interested in SUDA's pipeline and OroMist drug delivery technology
- Presenting at the AusBiotech Connect Colorado Business Networking Reception - 18 June 2014 in Denver, CO
- Presenting at the Australian Life Science Investment Showcase - 20 June 2014 in San Francisco, CA

PERTH, AUSTRALIA – 17 June 2014: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces the commencement of the second phase of its outreach to prospective licensees, acquirers and collaborators within the pharmaceutical industry.

The Company initiated its outreach in Europe in March 2014. This second phase is targeting the USA. Stephen Carter (CEO) and Nick Woolf (Chief Business Officer) are part of the Australian biotech delegation that is attending and exhibiting at the BIO International Convention, being held at the San Diego Convention Centre, CA, on 23-26 June 2014.

The convention is the largest, most influential global industry conference, which attracts the biggest names in the pharmaceutical and biotech sector, offering key networking and partnering opportunities. SUDA has scheduled meetings with 38 international pharmaceutical companies at this event, which is the Company's maximum meeting capacity, despite there being interest from more pharmaceutical companies. The interest spans ArTiMist™, SUDA's antimalarial sublingual spray, and the Company's other advanced clinical-stage oral sprays, as well as the application of SUDA's OroMist drug delivery technology to new drugs.

In addition to the BIO International Convention, SUDA is participating in two other satellite events in the USA:

- Stephen Carter is presenting at the AusBiotech Connect Colorado Business Networking Reception on 18 June 2014 in Denver, CO. This event is intended to build connections between Australian and Colorado industry executives. Attendees include venture capitalists, medical foundations, patient advocacy groups, venture philanthropy, angels, pharmaceutical and medtech companies: <http://www.cobioscience.com/events-calendar/ausbiotech-connect-colorado>

- Nick Woolf is presenting at the Australian Life Science Investment Showcase on 20 June 2014 in San Francisco, CA. AusBiotech together with US investment bank, Cowen and Company, are hosting this event. The Showcase has become an important event on the calendar for US investors interested in life sciences and looking for an overview of Australia's top companies within the sector: <http://www.ausbiotech.org/events/?state=Internat>

Commenting on SUDA's outreach in the USA, Mr Stephen Carter, Chief Executive Officer of SUDA said: "This is an exciting period for SUDA. The interest from international pharmaceutical companies in our pipeline and our OroMist drug delivery technology has exceeded our expectations. We expect the second phase of our outreach, which is targeted at the USA, to attract more prospective partners. Given this attention from the industry, we remain confident in achieving our goals on our stated timelines."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's most advanced product is a novel sub-lingual treatment, ArTiMist™, for severe malaria in children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other development stage products include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting and erectile dysfunction. For more information, visit www.sudaltd.com.au